1497p * lessons from the past: long-term safety and efficacy outcomes of a prematurely terminated, randomized phase iii trial of precautionary versus hemoglobin-based erythropoietin administration for chemotherapy-associated anemia in patients with solid tumors

Conclusions: Prophylactic administration of ESA for CIA in patients with solid tumors was associated with increased incidence of a composite of thrombosis-related adverse events, especially in patients receiving adjuvant treatment, but did not have a detrimental impact on relapse/progression and survival rates.Disclosure: All authors have declared no conflicts of interest.

Source: Annals of Oncology - September 24, 2014 Category: Cancer & Oncology Authors: Mountzios, G., Aravantinos, G., Kouvatseas, G., Karina, M., Samantas, E., Papakostas, P., Skarlos, D., Galani, E., Kalofonos, H., Makatsoris, T., Bafaloukos, D., Pectasides, D. G., Fountzilas, G. Tags: supportive care Source Type: research